Tariffs, and their potential detrimental impacts on vehicle affordability, company profits, global competitiveness, and ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Alphabet posted strong Q2 results with broad-based growth, resilient Search performance, and an attractive valuation. Learn ...

aTyr Pharma shares were 31% higher, at $6.89, after the company said that the last patient has completed their last visit in the company's Phase 3 study of its lead therapeutic candidate, efzofitimod, ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer witnessed a dramatic 45.77% surge in trading volume, reaching a staggering 11.97 billion shares. Pfizer's stock price ...

Knowing that stock price performance is mainly driven by EPS growth ... Investors should monitor product pipelines, trial data, and guidance for confirmation. Like LLE, PFE has fallen to approximately ...

Shares of Pfizer Inc. PFE rallied 3.63% to $25.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...